By Engineva Research Team
SR&ED, Neurotechnology, Life Sciences Innovation
The Rise of a New Frontier in Mental Health Innovation
Over the past decade, Canada has quietly become a global leader in psychedelic science and neurotechnology — two fields converging to redefine how we understand and treat the brain.
From breakthroughs in brain-computer interfaces (BCIs) and neurostimulation systems to renewed inquiry into psychedelic-assisted therapies, Canadian innovators are driving a new era in mental and neurological health research.
Yet this work is not without challenges. These projects demand complex experimentation, long development cycles, and significant technical risk. For emerging companies, that risk raises a key question:
How can we fund this kind of research sustainably?
One of the most effective answers lies in leveraging Canada’s Scientific Research and Experimental Development (SR&ED) program — a cornerstone of the country’s innovation ecosystem.
Why Psychedelic and Neurotechnology Research Qualifies for SR&ED
SR&ED rewards companies that advance scientific or technological knowledge through systematic investigation.
In neurotechnology and psychedelic science, uncertainty is not the exception — it’s the foundation.
1. High Scientific Uncertainty
Projects often explore untested hypotheses, such as:
- Can novel electrode arrays capture higher-fidelity neural signals without signal drift?
- Can psilocybin or DMT analogues safely induce measurable neuroplasticity in specific brain regions?
These are unresolved scientific questions, not routine product development — and precisely what SR&ED is designed to support.
2. Experimentation as a Process
Both domains demand structured experimentation — from algorithmic modeling of brain activity to clinical trial design for psychedelic compounds.
Each iteration builds knowledge, aligns with CRA’s definition of systematic investigation, and can qualify for SR&ED incentives.
3. Alignment with National Priorities
Mental health, neurological disorders, and life sciences are now explicit priorities in Canada’s innovation agenda.
Research at this intersection contributes to national well-being, economic competitiveness, and public health — making it well-positioned for funding support.
4. Strong Commercialization Potential
Whether it’s a wearable EEG diagnostic or a novel serotonergic compound, the end goal is market impact.
SR&ED recognizes that commercially viable science often begins in high-uncertainty environments — and provides the financial infrastructure to help it reach reality.
Examples of Qualifying R&D Activities
In neurotechnology and psychedelic research, SR&ED-eligible activities often include:
- Developing AI algorithms to interpret complex neural data
- Designing closed-loop neurostimulation systems that respond to real-time brain signals
- Creating biosensors integrating neural and physiological metrics for feedback
- Conducting dose-response optimization studies for novel psychedelic compounds
- Building simulation models to test compound–receptor interactions
- Developing neuroimaging software to analyze brain activity during altered states of consciousness
Each of these involves iterative experimentation under technological or scientific uncertainty — a textbook case for SR&ED eligibility.
Beyond SR&ED: Canada’s Expanding R&D Funding Ecosystem
While SR&ED remains the foundation of R&D funding in Canada, companies in life sciences and neurotechnology can amplify their support by layering complementary programs.
A coordinated funding strategy can recover 50–60% of total technical labour and experimentation costs through federal and provincial mechanisms, such as:
- IRAP (Industrial Research Assistance Program): Early-stage prototyping and validation
- Strategic Innovation Fund (SIF): Large-scale technology commercialization
- SDTC (Sustainable Development Technology Canada): Clean and sustainable healthcare innovations
- Mitacs & NSERC: Collaborative projects with universities or research institutes
- Provincial Innovation Funds: Matching or extending federal programs
By combining SR&ED with these supports, innovators can reduce financial risk, accelerate discovery, and maintain long-term research continuity.
Maximizing SR&ED Benefits in Neuroscience and Psychedelics
To capture full SR&ED value, companies should focus on three core best practices:
1. Build Documentation into Your Workflow
Maintain experiment logs, meeting summaries, and data analyses as work happens.
Contemporaneous evidence is critical for demonstrating systematic experimentation.
2. Frame Your Uncertainties Clearly
Describe what was unknown, not just what was done.
For example:
“It was uncertain whether multi-electrode feedback could maintain stability over long-duration sessions.”
This phrasing communicates a scientific objective, not just engineering activity.
3. Engage Expertise Early
Work with SR&ED and innovation funding specialists familiar with life sciences and clinical R&D.
They can identify all eligible work, align documentation with CRA expectations, and coordinate overlapping programs for maximum recovery.
The Future of Brain Science Innovation in Canada
Neurotechnology and psychedelic research are redefining the boundaries of science and medicine.
Their convergence could unlock breakthroughs in mental health, cognitive restoration, and neurological diagnostics — but only if innovators have the resources to explore the unknown.
By strategically leveraging Canada’s R&D funding ecosystem, with SR&ED at its core, companies can:
- Recover a significant share of experimental costs
- Reinvest in discovery
- Build the financial resilience to sustain long-term research
Innovation in this field isn’t just about advancing science — it’s about building the infrastructure to sustain it.
At Engineva, we help forward-thinking innovators in neuroscience, digital therapeutics, and life sciences turn their R&D into recoverable value.
Our team identifies eligible experimental work, optimizes SR&ED and grant strategies, and ensures compliance with evolving CRA and funding program standards.
📞 Book a consultation to explore how your neurotechnology or psychedelic research can qualify for R&D funding — and secure the financial foundation to push scientific boundaries responsibly and confidently.